Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Language
Publication year range
1.
Hipertens. riesgo vasc ; 38(4): 170-177, oct.-dic. 2021. tab
Article in English | IBECS | ID: ibc-221317

ABSTRACT

Objective: The use of cyclosporine A (CsA) is associated with different adverse effects including hypertension and nephrotoxicity. The present study aimed to compare the inhibitory effects of l-arginine & l-citrulline on CsA-induced blood pressure and biochemical changes in the serum of rats. Methods: Thirty-six rats were divided into 6 groups received daily: (1) 1ml distilled water, (2) 200mg/kg l-citrulline IP, (3) 25mg/kg CsA SC, (4) CsA+l-citrulline with the same dose of the former groups, (5) 200mg/kg l-arginine IP and (6) l-arginie+CsA with the same doses of group 4 for 7 days. Results: The changes in the blood pressure, heart rate, creatinine, BUN, glucose and C-reactive protein (CRP) of the serum were determined in the treated animals. Significant (p<0.001) increase was shown in the blood pressure and heart rate of CsA treated rats compared to the control group. There were also a significant (p<0.05) increase in the creatinine, BUN and glucose, but a decrease in the CRP value in the CsA-treated group. However, l-citrulline significantly (p<0.001) inhibited the changes in the blood pressure and heart rate in CsA-treated as well as it was able to reduce blood pressure in non-treated group significantly (p<0.01). l-citrulline also inhibited the increased levels of BUN and creatinine induced by CsA, while, l-arginine was able to prevent the increased blood pressure and creatinine occurs after administration of CsA. Conclusions: These findings suggest that the l-citrulline is more efficient than l-arginine against the adverse effects induced by cyclosporine. (AU)


Objetivo: El uso de ciclosporina A (CsA) está asociado a diferentes efectos adversos que incluyen hipertensión y nefrotoxicidad. El objetivo del presente estudio es comparar los efectos inhibitorios de L-arginina y L-citrulina en la presión arterial inducida por CsA, y los cambios bioquímicos a nivel sérico en ratas. Métodos: Se dividieron 36 ratas en 6 grupos, que recibieron diariamente: 1) 1ml de agua destilada, 2) 200mg/kg de L-citrulina IP, 3) 25mg/kg de CsA SC, 4) la misma dosificación que los grupos anteriores de CsA+L-citrulina, 5) 200mg/kg de L-arginina IP y 6) la misma dosificación que el grupo 4 durante 7 días de L-arginina+CsA. Resultados: Se determinaron los cambios de presión arterial, frecuencia cardiaca, creatinina, BUN, glucosa y proteína C reactiva (PCR) a nivel sérico, en los animales tratados. Se observó un incremento significativo (p<0,001) de presión arterial y frecuencia cardiaca en las ratas tratadas con CsA en comparación con el grupo control. También se produjo un incremento significativo (p<0,05) de los niveles de creatinina, BUN y glucosa, y una reducción del valor de PCR en el grupo tratado con CsA. Sin embargo, L-citrulina inhibió significativamente (p<0,001) los cambios de presión arterial y frecuencia cardiaca en las ratas tratadas con CsA, y también pudo reducir la presión arterial de manera considerable en el grupo no tratado (p<0,01). L-citrulina inhibió también los niveles incrementados de BUN y creatinina inducidos por CsA, y L-arginina fue capaz de impedir la incidencia del incremento de presión arterial y creatinina tras la administración de CsA. Conclusiones: Estos hallazgos sugieren que L-citrulina es más efectiva que L-arginina frente a los efectos adversos inducidos por ciclosporina. (AU)


Subject(s)
Animals , Rats , Arterial Pressure , Citrulline/adverse effects , Arginine/adverse effects , Immunosuppressive Agents , Creatinine , Cyclosporine , Glucose , Kidney Diseases
2.
Clin. transl. oncol. (Print) ; 23(10): 2181-2190, oct. 2021.
Article in English | IBECS | ID: ibc-223389

ABSTRACT

Purpose Chimeric antigen receptor (CAR) T cell development for B cell malignancies treatment has triggered a paradigm shift in oncology. The development of anti-CD19 CAR T cells relies primarily on a panel of cell line-derived xenograft models, including Raji cells; however, the behavior of this model is under debate. We attempted to characterize this lymphoma model and propose outcome measures for CAR T cell studies Methods Raji cell line was inoculated into NOG mice via intra-venous (IV), intra-peritoneal (IP), and subcutaneous (SC) routes with different inoculum sizes, and consequent clinical and histopathological outcomes were assessed. Results Inoculum sizes of 105–106 resulted in a complete take rate. The mice with IV and SC-inoculated Raji cells presented the shortest and longest survival among lymphoma-bearing mice, respectively (P < 0.01). The IP group had the highest number of both infiltrated organs (P < 0.05; compared to SC) and involvement of lymphatic sites (P < 0.05; compared to IV). The number of lymphoma lesions on the liver was higher in the IV compared to IP (P < 0.001) and SC (P < 0.05). Conclusion We demonstrate that the Raji cell line inoculation route could determine the xenograft model system behavior in terms of survival, tumor burden, and dissemination pattern and gives the model the specific features suitable for testing the specific hypothesis in CAR T cell therapy. We also conclude outcome measures for CAR T cell studies that do not require imaging techniques (AU)


Subject(s)
Animals , Male , Female , Mice , Antigens, CD19/immunology , Immunotherapy, Adoptive/methods , Lymphoma, Non-Hodgkin/therapy , Receptors, Chimeric Antigen , Xenograft Model Antitumor Assays , Cell Line, Tumor , Disease Models, Animal , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/pathology , Mice, Inbred NOD , Neoplasm Invasiveness , Random Allocation , T-Lymphocytes/immunology , Body Weight
3.
Hipertens Riesgo Vasc ; 38(4): 170-177, 2021.
Article in English | MEDLINE | ID: mdl-34561200

ABSTRACT

OBJECTIVE: The use of cyclosporine A (CsA) is associated with different adverse effects including hypertension and nephrotoxicity. The present study aimed to compare the inhibitory effects of l-arginine &l-citrulline on CsA-induced blood pressure and biochemical changes in the serum of rats. METHODS: Thirty-six rats were divided into 6 groups received daily: (1) 1ml distilled water, (2) 200mg/kg l-citrulline IP, (3) 25mg/kg CsA SC, (4) CsA+l-citrulline with the same dose of the former groups, (5) 200mg/kg l-arginine IP and (6) l-arginie+CsA with the same doses of group 4 for 7 days. RESULTS: The changes in the blood pressure, heart rate, creatinine, BUN, glucose and C-reactive protein (CRP) of the serum were determined in the treated animals. Significant (p<0.001) increase was shown in the blood pressure and heart rate of CsA treated rats compared to the control group. There were also a significant (p<0.05) increase in the creatinine, BUN and glucose, but a decrease in the CRP value in the CsA-treated group. However, l-citrulline significantly (p<0.001) inhibited the changes in the blood pressure and heart rate in CsA-treated as well as it was able to reduce blood pressure in non-treated group significantly (p<0.01). l-citrulline also inhibited the increased levels of BUN and creatinine induced by CsA, while, l-arginine was able to prevent the increased blood pressure and creatinine occurs after administration of CsA. CONCLUSIONS: These findings suggest that the l-citrulline is more efficient than l-arginine against the adverse effects induced by cyclosporine.


Subject(s)
Blood Pressure , Animals , Arginine , Citrulline , Creatinine , Cyclosporine , Glucose , Immunosuppressive Agents , Kidney , Kidney Diseases , Rats
4.
Clin Transl Oncol ; 23(10): 2181-2190, 2021 Oct.
Article in English | MEDLINE | ID: mdl-33942221

ABSTRACT

PURPOSE: Chimeric antigen receptor (CAR) T cell development for B cell malignancies treatment has triggered a paradigm shift in oncology. The development of anti-CD19 CAR T cells relies primarily on a panel of cell line-derived xenograft models, including Raji cells; however, the behavior of this model is under debate. We attempted to characterize this lymphoma model and propose outcome measures for CAR T cell studies METHODS: Raji cell line was inoculated into NOG mice via intra-venous (IV), intra-peritoneal (IP), and subcutaneous (SC) routes with different inoculum sizes, and consequent clinical and histopathological outcomes were assessed. RESULTS: Inoculum sizes of 105-106 resulted in a complete take rate. The mice with IV and SC-inoculated Raji cells presented the shortest and longest survival among lymphoma-bearing mice, respectively (P < 0.01). The IP group had the highest number of both infiltrated organs (P < 0.05; compared to SC) and involvement of lymphatic sites (P < 0.05; compared to IV). The number of lymphoma lesions on the liver was higher in the IV compared to IP (P < 0.001) and SC (P < 0.05). CONCLUSION: We demonstrate that the Raji cell line inoculation route could determine the xenograft model system behavior in terms of survival, tumor burden, and dissemination pattern and gives the model the specific features suitable for testing the specific hypothesis in CAR T cell therapy. We also conclude outcome measures for CAR T cell studies that do not require imaging techniques.


Subject(s)
Antigens, CD19/immunology , Immunotherapy, Adoptive/methods , Lymphoma, Non-Hodgkin/therapy , Receptors, Chimeric Antigen , Xenograft Model Antitumor Assays/methods , Animals , Body Weight , Cell Line, Tumor , Disease Models, Animal , Female , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/pathology , Male , Mice , Mice, Inbred NOD , Neoplasm Invasiveness , Random Allocation , T-Lymphocytes/immunology
SELECTION OF CITATIONS
SEARCH DETAIL